NewEdge Advisors’s AGF US Market Neutral Anti-Beta Fund BTAL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-2,547
Closed -$50.6K 3759
2023
Q3
$50.6K Sell
2,547
-44,124
-95% -$836K ﹤0.01% 2092
2023
Q2
$876K Buy
46,671
+6,340
+16% +$128K 0.01% 930
2023
Q1
$823K Buy
40,331
+26,778
+198% +$539K 0.01% 875
2022
Q4
$128K Buy
+13,553
New +$281K ﹤0.01% 1344
2021
Q4
Sell
-10,983
Closed -$187K 1642
2021
Q3
$187K Sell
10,983
-1,868
-15% -$32K ﹤0.01% 1062
2021
Q2
$218K Buy
12,851
+721
+6% +$12.2K 0.01% 1017
2021
Q1
$208K Sell
12,130
-80,178
-87% -$1.44M 0.01% 933
2020
Q4
$1.76M Buy
92,308
+30,335
+49% +$634K 0.06% 283
2020
Q3
$1.46M Buy
61,973
+29,988
+94% +$718K 0.05% 302
2020
Q2
$779K Buy
31,985
+23,541
+279% +$581K 0.03% 420
2020
Q1
$217K Buy
+8,444
New +$201K 0.01% 685

Other funds holding BTAL

NewEdge Advisors's BTAL Position: Q4 2023 in Review

NewEdge Advisors sold out of AGF US Market Neutral Anti-Beta Fund (BTAL) in Q4 2023, closing a stake of 2,547 shares — an estimated $50.6K sold.

NewEdge Advisors first reported a position in BTAL in Q1 2020 and held it in 11 quarters. The position peaked at $1.76M in Q4 2020. 75 funds tracked by Wall St. Rank hold BTAL as of Q4 2023.

  • NewEdge Advisors reported no remaining AGF US Market Neutral Anti-Beta Fund position as of Q4 2023 after selling out during the quarter.
  • NewEdge Advisors sold 2,547 AGF US Market Neutral Anti-Beta Fund shares in Q4 2023, an estimated $50.6K.
  • NewEdge Advisors first reported a position in AGF US Market Neutral Anti-Beta Fund in Q1 2020 and held it in 11 quarters.
  • NewEdge Advisors's AGF US Market Neutral Anti-Beta Fund position peaked at $1.76M in Q4 2020.
  • 75 funds tracked by Wall St. Rank held AGF US Market Neutral Anti-Beta Fund as of Q4 2023.

Based on NewEdge Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.